The phenotypic expression of left ventricular hypertrophy (LVH) in patients with hypertrophic cardiomyopathy (HCM) is variable. This phenotypic variability is not completely explained by the responsible mutations or other known factors. Recent data denote a role for the modifier genes and environmental factors. We studied the role of 3 potential modifier genes, ie, angiotensinogen (AGT), angiotensin II receptor 1, (AT1), and endothelin-1 (END1) on the phenotypic expression of LVH in patients with hypertrophic cardiomyopathy (HCM).
Methods
The study population was comprised of 108 genetically independent patients with HCM. Left ventricular mass index (LVMI) and LVH score were determined per published protocols. The genotypes of AGT (M235T, T174M, and G-6A), AT1, and END1 were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) or mutation-specific PCR (MS-PCR).
Results
Male patients had higher mean LVMI and LVH score than female patients (146.0 ± 33.5 vs 129.4 ± 33.6, p = 0.01 and 6.0 vs 5.0, p = 0.010, respectively). Gender accounted for 4.8% and 5.4% of the variability of LVMI and LVH score, respectively. The END1 genotypes also had a significant influence on LVH scores accounting for 2.9% of their variability (p = 0.042). The median LVH score was greater in patients with the AA and AG genotypes, as compared to patients with the GG genotype (7.0 vs 5.0, p = 0.034). Neither the AGT nor the AT1 genotypes had a significant influence on the expression of LVH. In multivariate regression analysis, END1 and gender accounted for 7.3% of the variability of the LVH score (p = 0.007).
Conclusions
Our results show that gender and the END1 gene modify the phenotypic expression of hypertrophy in patients with HCM.
MarianAJ, RobertsR.Recent advances in the molecular genetics of hypertrophic Cardiomyopathy. Circulation1995;92:1336–47.
2.
Geisterfer-LawranceAA, KassS, TanigawaG, VosbergHP, McKennaW, SeidmanCE, SeidmanJG. A molecular basis for familial hypertrophic cardiomyopathy: a β-cardiac myosin heavy chain gene missense mutation. Cell1990; 62:999–1006.
3.
ThierfelderL, WatkinsH, MacRaeC, LamasR, McKennaW, VosbergH-P, SeidmanJG, SeidmanCEoa-Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere. Cell1994;77: 701–12.
4.
WatkinsH, ConnerD, ThierfelderL, JarchoJA, MacRaeC, McKennaWJ, MaronBJ, SeidmanWJ, SeidmanCEoMutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet1995;11:434–7.
PoetterK, JiangH, HassanzadehS, MasterS, ChangA, DalakasMC, RaymentI, SellersJR, FananapazirL, EpsteinND. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet1996;13:63–9.
7.
MacRaeC, GhasiaN, KassS, DonnellyS, BassonCT, WatkinsH, AnanR, ThierfelderLH, McGarryK, RowlandE, McKennaW, SeidmanIO, SeidmanCEoFamilial hypertrophic cardiomyopathy with Wolfe-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Inves1995;96:1216–20.
8.
EpsteinND, CohnGM, CyranF.FananapazirL.Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the β-myosin heavy chain gene: a 908 Leu-Val mutation and a 403 Arg-Gln mutation. Circulation1992;86:345–52.
9.
MarianAJ, MaresAJr., KellyDP, YuQT, AbcheeAB, HillR.RobertsR.Sudden cardiac death in hypertrophic cardiomyopathy: variability in phenotypic expression of beta-myosin heavy chain mutations. Eur Heart J1995;16: 368–76.
10.
SolomonSD, WolffSA, WatkinsH, RidkerPM, ComeP, McKennaWJ, SeidmanCE, LeeRT. Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coil Cardiol1993;22:498–505.
11.
WatkinsH, RosenweigA, HwangD, LeviT, McKennaW, SeidmanCE, SeidmanJG. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med1992;326: 1108–14.
12.
WatkinsH, McKennaWJ, ThierfelderL, SukHJ, AnanR, O'DonoghueA, SpiritoP, MatsumoriA, MoravecCS, SeidmanJG; SeidmanCEoMutations in the genes for cardiac troponin and a tropomyosin in hypertrophic cardiomyopathy. N Engl J Med1995;332: 1058–64.
13.
FananapazirL, EpsteinND. Genotype-phenotype correlation in hypertrophic cardiomyopathy: insights provided by comparisons of kindreds with distinct and identical β-myosin heavy chain gene mutations. Circulation1994;89:22–32.
14.
AnanR, GreveG, ThierfelderL, WatkinsHC, McKennaWJ, SolomonS, VecchioC, ShonoH, NakaoS, TanakaH, MaresAJr, TowbinJA, SpiritoP, RobertsR, SeidmanJG, SeidmanCEoPrognostic implications of novel β-cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest1994;93:280–5.
15.
A~cheeA: Ma. rianAJ.. Prognostic significance of β-myosin heavy cham mutations IS reflective of their hypertrophic expressivity in patients with hypertrophic cardiomyopathy. J Investig Med1997;45:191–6.
16.
LechinM, QuinonesM, OmranA, HillR, YuQ-T, RakowskiH, WigleD, LiewCC, SoleM, RobertsR, MarianAJ. Angiotensin converting enzyme genotype DD IS associated with increased left ventricular mass in patients with hypertrophic cardiomyopathy. Circulation1995;92:1808–12.
17.
SchillerNB, ShahPM, CrawfordM, DeMariaA, DevereuxR, FelgenbaumH, GutgessellH, ReichekN, SahnD, SchnittgerI, Sllver~anNH, TaJlkAJ. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two Dimensional Echocardiograms: Recommendations for Quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr1989;2:358–67.
18.
WigleD.' SassonZ, HendersonMA, RuddyTD, FulopJ, RakowskiH, WilliamsWG. Hypertrophic cardiomyopathy: the importance of the site and extent of hypertrophy: a review. Prog Cardiovasc Dis1985;28:1–83.
19.
RakowskiH, SassonZ, WigleED. Echocardiographic and Doppler assessment of hypertrophic cardiomyopathy. J Am Soc Echccardiogr1988;1:31–47.
20.
MillerSA, DykesDD, PoleskyHF. A simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res1988;16:1215.
21.
JeunemaitreX, SoubrierF, KotelevtsevYV, LiftonRP, WilliamsCS, CharruA, HuntSC, HopkinsPN, WilliamsRR, LalouelJ-M, CorvolP.Molecular basis of human hypertension: role of angiotensinogen. Cell1992;71:169–80.
22.
CaufieldM, LavenderP, FarrallM, MunroeP, LawsonM, TurnerP, ClarkAJL. Linkage of the angiotensinogen gene to essential hypertension. New Engl J Med1994;330:1629–33.
23.
InoueI, NakajimaT, WilliamsCS, QuackenbushJ, PuryearR, PowersM, ChengT, LudwigEH, SharmaAM, HataA, JeunemaitreX, LalouelJ-M. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest1997;99: 1786–97.
24.
RussAP, MaerzW, RuzickaV, SteinU, GroβW.Rapid detection of the hypertension-associated Met235 Thr allele of the human angiotensionogen gene. Hum Mol Genet1993;2:609–10.
25.
BonnardeauxA, DaviesE, JeunemaitreX, FeryI, CharruA, ClauserE, TiretL, CambienF, CorvolP, SoubrierF.Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension1994;24:63–9.
26.
BergeKE, BergK.A TaqI RFLP at the ENDI gene locus. Nucleic Acid Res1990;18:6176.
27.
InoueA, YanagisawaM, TakuwaY, MitsuiY, KobayashiM, MasakiT.The human preproendothelin-l gene: complete nucleotide sequence and regulation of expression. J Bioi Chern1989;264: 14954–9.
28.
IshanovA, OkamotoH, YoneyaK, WatanabeM, NakagawaI, MachidaM, OnozukaH, MikamiT, KawagushiH, HataA, KondoK, KitabatakeA.Angiotensinogen gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Am Heart J1997;133:184–9.
29.
AdamsTD, YanowitzFG, FisherAG. RdigesJD, NelsonAG, HaganAD, WilliamsRR, HuntSC. Heritability of cardiac size: an echocardiographic and electrocardiographic study of monozygotic and dizygotic twins. Circulation1985;71:39–44.
30.
VerhaarenHA, SchiekenRM, MostellerM, HewittJK, EavesU, NanceWE. Bivariate genetic analysis of left ventricular mass and weight in pubertal twins (The Medical College of Virginia Twin Study). AmJCardioI1991;68:661–8.
31.
SchunkertH, HenseH-W, HolmerSR, StenderM, PerzS, KeilU, LorellBH, ReiggerGAJ. Association between a deletion polymorphism of the angiotensin-converting enzyme gene and left ventricular hypertrophy. N Engl J Med1994;330:1634–8.
32.
PravenecM, GauguierD, SchottJJ, BuardJ, KrenV, BillaV, SzpirerC, SzpirerJ, WangJM, HuangH, et al. Mapping of quantitative trait loci for blood pressure and cardiac mass in the rat by genome scanning of recombinant inbred strains. J Clin Invest1995;96: 1973–8.
33.
MarianAJ, YuQ-T, WorkmanR, GreveG, RobertsR.Angiotensin converting enzyme polymorphism is associated with hypertrophic cardiomyopathy as well as sudden cardiac death. Lancet1993;342:1073–4.
34.
InoueA, YanagisawaM, KimuraS, KasuyaY, MiyauchiT, GotoK, MasakiT.The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci1989;86:2863–7.
35.
ItoH, HirataY, HiroeM, TsujinoM, AdachiS, TakamotoT, NittaM, TaniguchiK, MarumoF.Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res1991;69:209–15.
36.
ShbeitaHE, McDonoughPM, HarrisAN, KnowltonKU, GlembotskiCC, BrownJH, ChienK.Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes: a paracrine mechanism for myocardial cell hypertrophy. J Biol Chem1990;265:20555–62.
37.
ItoH, HiroeM, HirataY, FujisakiH, AdachiS, AkimotoH, OhtaY, MarumoF.Endothelin ET, receptor anatagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation1994;89:2198–208.
38.
WangDL, ChenJJ, ShinNL, KaoYC, HsuKH, HuangWY, LiewCC. Endothelin stimulates cardiac a and β-myosin heavy chain gene expression. Biochem Biophys Res Comm1992;183:1260–5.
39.
IchikawaK-I, HidaiC, OkudaC, KimataS-I, MatsuokaR, HosodaS, QuertermousT, KawanaM.Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rat ventricular myocardium. J Am Coll Cardiol1996;27:1286–91.
40.
HasegawaK, FujiwaraH, KoshijiM, InadaT, OhtaniS, DoyamaK, TanakaM, MatsumoriA, FujiwaraT, ShirakamiG, HosodaK, NakaoK, SasayamaS.Endothelin-1 and its receptor in hypertrophic cardiomyopathy. Hypertension1996;27:259–64.
41.
TiretL, BonnardeauxA, PoirierO, RicardS, Marques-VidalP, EvansA, ArveilerD, LucG, KeeF, DucimetiereP, SoubrierF, CambienF.Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet1994;344:910–3.
42.
MarianAJ. YuQ-T, MannD, GrahamF, RobertsR.Expression of the mutation causing hypertrophic cardiomyopathy disrupts sarcomere assembly in adult feline cardiac myocytes. Circ Res1995;77:98–106.
43.
LankfordEB, EpsteinND, FananapazirL, SweeneyHL. Abnormal contractile properties of muscle fibers expressing β-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J Clin Invest1995;95:1409–14.
44.
WatkinsH, SeidmanCE, SeidmanJG, FengHS, SweeneyHL. Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action. J Clin Invest1996;98:2456–61.
45.
CudaG, FananapazirL, ZhuW, SellersJR, EpsteinND. Skeletal muscle expression and abnormal function of beta myosin in hypertrophic cardiomyopathy. J Clin Invest1993;91:2861–5.
46.
MarianAJ. ZhaoG, SetaY, RobertsR, YuQ-T. Expression of a mutant (Arg2Gln) human cardiac troponin T, known to cause hypertrophic cardiomyopathy, impairs adult cardiac myocytes contractility. Circ Res1997;81:76–85.
47.
HengstenbergC, MaischB.Increased nuclear proto-oncogene expression in hypertrophic cardiomyopathy. Cardioscience1993;1:15–20.
48.
DerchiG, BelloneP, ChiarellaF, RandazzoM, ZinoV, VecchiC.Plasma levels of atrial natriuretic peptide in hypertrophic cardiomyopathy. Am J Cardiol1992;70:1502–4.
49.
HasegawaK, FujiwaraH, DoyamaK, MiyamaeM, FujiwaraTТ, SugaS, MukoyamaM, NakaoK, ImuraH, SasayamaS.Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circ1993; 88: 372–380.
